Yes! You can switch from Saxenda to Wegovy and for many patients it’s a straightforward transition that can deliver significantly better results. Both are GLP-1 receptor agonist injections, so your body is already familiar with the mechanism. The main differences are the active ingredient, the dosing frequency and the clinical evidence behind each treatment.
Saxenda vs Wegovy: what’s the difference?
Before looking at how to switch, it helps to understand what differs between these two treatments.
Both medications work by mimicking the GLP-1 hormone, which helps you feel full sooner, stay full longer and slows down how quickly food leaves your stomach. The main difference is how long they stay active in the body. Wegovy lasts longer so it only needs to be taken once a week and keeps a steadier effect throughout the week. Saxenda doesn’t last as long so it needs to be taken every day to keep working consistently.
Why patients switch from Saxenda to Wegovy
There are several common reasons why patients make this change.
Saxenda is being discontinued in the UK. Novo Nordisk (the manufacturers) have announced the discontinuation of Saxenda, meaning supply is already limited in many UK pharmacies. Patients currently on Saxenda will need to transition to an alternative treatment.
Better weight loss outcomes. Clinical trials consistently show Wegovy delivers around double to triple the weight loss of Saxenda. For patients who have plateaued or not reached their goals on Saxenda, switching makes clinical sense.
Convenience. Moving from a daily injection to a once-weekly pen is a significant lifestyle improvement for many patients and better adherence typically means better results.
Tolerability. Some patients find the constant daily top-up of Saxenda causes persistent mild nausea. The once-weekly Wegovy schedule can reduce this.
Cardiovascular benefits. Wegovy is also approved to help reduce the risk of serious heart problems, such as heart attacks and strokes, in adults who already have cardiovascular disease. This added heart-health benefit is not currently approved for Saxenda.
Saxenda to Wegovy dose conversion
This is often the part patients have the most questions about. Although Saxenda and Wegovy work in similar ways, they are different medications and come in different strengths. That means there isn’t a simple “like-for-like” dose swap between the two.
Key points about the conversion
A washout period is needed. You can safely start Wegovy after a 10 day wash out period following your last Saxenda dose.
Starting lower than you might expect is intentional. Even if you were on the full 3.0mg Saxenda dose, you’ll typically start Wegovy at 0.25mg rather than jumping to a higher dose. This conservative approach helps reduce the chance of side effects while giving your body time to adjust to the new medication.
Titration continues as normal. From your starting dose you’ll increase every four weeks following the standard Wegovy schedule: 0.25mg then 0.5mg, 1.0mg, 1.7mg and up to 2.4mg. For some patients the higher 7.2mg dose is also an option.
Do not take both medications simultaneously. Overlapping two GLP-1 treatments increases side effect risk without any additional clinical benefit.
Wegovy vs Saxenda side effects: what changes when you switch?
The side effect profiles of both medications are similar, which makes sense given they work through the same GLP-1 pathway. However, there are meaningful differences in how and when side effects tend to appear.
Side effects shared by both treatments
- Nausea and vomiting
- Diarrhoea or constipation
- Stomach pain or discomfort
- Headache
- Fatigue
- Dizziness
- Gallstones
- Injection site reactions
How the experience differs
On Saxenda, the medication is topped up every 24 hours which means mild side effects like nausea can feel more persistent. You’re essentially resetting the cycle daily.
On Wegovy, side effects tend to cluster in the day or two following each injection, then ease off. For many patients, this pattern is easier to manage and plan around.
Research suggests that Wegovy may be easier for many people to tolerate than Saxenda. In one clinical trial, around 28% of people taking Saxenda stopped treatment because of side effects, compared with about 14% of people taking Wegovy. This matters as people who are able to stay on treatment for longer are more likely to achieve and maintain better weight loss results.
Additionally, Wegovy doses are increased more gradually than Saxenda, giving your body extra time to adjust. Even so, some people may still notice stronger side effects, such as nausea or stomach discomfort, when moving up to higher doses. That’s why we usually recommend starting on a lower dose and increasing slowly over time to make treatment as comfortable and manageable as possible.
For detailed guidance on managing nausea, bloating, and digestive symptoms on Wegovy, visit our common Wegovy side effects guide.
How to switch from Saxenda to Wegovy safely
The switch is straightforward when done with clinical oversight. Here’s what the process looks like in practice.
Complete our online consultation. One of our prescribers will review your current Saxenda dose, treatment history, any side effects you’ve experienced and your overall progress.
Take your last Saxenda dose. Allow for a 10-day washout period before starting Wegovy.
Start Wegovy at 0.25mg.
Titrate every 4 weeks. Follow the standard Wegovy dose escalation schedule, increasing only when you’re tolerating the current dose well.
Monitor and check in. Track appetite changes, any digestive symptoms, and your weight trend. Report any side effects that aren’t manageable or that worsen significantly after a dose increase.
Who can switch?
To be eligible for Wegovy, you’ll usually need to meet the following criteria:
- You have a BMI of 30 or above
- You have a BMI of 27 or above alongside a weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
- The medication is considered safe for you to take, meaning you do not have any medical conditions or take any medicines that could cause problems or interactions.
- If you’re already taking a GLP-1 weight-loss medication and are switching to Phlo Clinic, you may still be eligible with a BMI of 23 or above, as long as you can provide supporting evidence of your current treatment.
Ready to make the switch?
At Phlo Clinic, our prescribing pharmacists are qualified to assess your suitability, guide you through the switch and support you with monthly check-ins throughout your treatment.
References
- Wadden TA et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. pmc.ncbi.nlm.nih.gov/articles/PMC8753508
- Medicines Information New Zealand. Switching from liraglutide (Saxenda) to semaglutide (Wegovy): dose conversion guidance. Published July 2025. medicinesinformation.co.nz
- VA Pharmacy Benefits Management Services. Semaglutide (Wegovy) Subcutaneous Injection Conversion Guidance for Weight Management. February 2023. va.gov
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002. nejm.org/doi/full/10.1056/NEJMoa2032183
- National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). Published March 2023. nice.org.uk
- Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy (semaglutide): summary of product characteristics. gov.uk
